Type I interferons in anticancer immunity

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838

The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors

Kawai, T., & Akira, S. (2010) · Nature Immunology · doi:10.1038/ni.1863 · Cited by 9,304

Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion

Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474

Innate and adaptive immune cells in the tumor microenvironment

Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148

Virus interference. I. the interferon

Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451

The Three Es of Cancer Immunoediting

Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,235

Type I interferons in infectious disease

McNab, F., Mayer-Barber, K., Sher, A., Wack, A., & O'Garra, A. (2015) · Nature Reviews Immunology · doi:10.1038/nri3787 · Cited by 2,780

STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

Deng, L., Liang, H., Xu, M., Yang, X., Burnette, B., Arina, A., Li, X.-D., Mauceri, H., Beckett, M., Darga, T., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.019 · Cited by 2,182

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Interferon-driven Metabolic Reprogramming and Tumor Microenvironment Remodeling

Chang, T.-H., & Ho, P. (2025) · Immune Network · doi:10.4110/in.2025.25.e8 · Cited by 19

Manipulation of Innate Immunity for Cancer Therapy in Dogs

Regan, D. P., & DOW, S. W. (2015) · Veterinary Sciences · doi:10.3390/vetsci2040423 · Cited by 17

Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner

Shuvalov, O. Y., Kizenko, A., Shakirova, A., Fedorova, O., Petukhov, A., Aksenov, N. D., Vasileva, E., Daks, A. A., & Barlev, N. A. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.118 · Cited by 17

Environmentally Triggerable Retinoic Acid-Inducible Gene I Agonists Using Synthetic Polymer Overhangs

Palmer, C. R., Jacobson, M. E., Fedorova, O., Pyle, A. M., & Wilson, J. T. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00697 · Cited by 17

Novel therapeutic strategies for advanced ovarian cancer by using induced pluripotent stem cell‐derived myelomonocytic cells producing interferon beta

Imamura, Y., Tashiro, H., Gandolgor, T.-A., Haruta, M., Narantuya, D., Komohara, Y., Tsuboki, J., Takaishi, K., Ohba, T., Nishimura, Y., et al. (2018) · Cancer Science · doi:10.1111/cas.13775 · Cited by 17

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma

Jia, D., Niu, Y.-L., Zhu, H., Wang, S., Ma, T., & Li, T. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.675873 · Cited by 17

Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors

Ji, X., Jiang, W., Wang, J., Zhou, B., Ding, W., Liu, S., Huang, H., Chen, G., & Sun, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1106644 · Cited by 18

Cyclophosphamide treatment regulates the balance of functional/exhausted tumor-specific CD8+T cells

Hanoteau, A., Henin, C., Švec, D., Donnet, C. B., Denanglaire, S., Colau, D., Romero, P. J., Léo, O., den Eynde, B. J. V., & Moser, M. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1318234 · Cited by 19

E3 ubiquitin ligase ANKIB1 attenuates antiviral immune responses by promoting K48-linked polyubiquitination of MAVS

Liu, W., Yuan, C., Fu, B., Xie, J., Li, W., Zhang, G., Ma, Z., & Jiao, P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114687 · Cited by 16

A pH-responsive PROTAC-based nanosystem triggers tumor-specific ferroptosis to construct in situ tumor vaccines

Huang, L., Sun, X., Zuo, Q., Song, T., Liu, N., Liu, Z., & Xue, W. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101523 · Cited by 16

Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies

Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 16

Oncolytic Viruses: Immunotherapy Drugs for Gastrointestinal Malignant Tumors

Li, Q., Oduro, P. K., Guo, R., Li, R., Leng, L., Kong, X., Wang, Q., & Yang, L. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.921534 · Cited by 16

Type I interferons, inflammation, and fatigue in a longitudinal RNA study of women with breast cancer

Bower, J. E., Ganz, P. A., Irwin, M. R., Crespi, C. M., Petersen, L., Asher, A., Hurvitz, S. A., & Cole, S. W. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.02.003 · Cited by 16

Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models

Onyshchenko, K., Luo, R., Rao, X., Zhang, X., Gaedicke, S., Grosu, A., Firat, E., & Niedermann, G. (2024) · Theranostics · doi:10.7150/thno.88864 · Cited by 16

Unveiling the Promise: Navigating Clinical Trials 1978–2024 for PDAC

Dominguez, A. A., Perz, M., Xu, Y., Cedillo, L. G., Huang, O. L., McIntyre, C. A., Vudatha, V., Trevino, J. G., Liu, J., & Wang, P. (2024) · Cancers · doi:10.3390/cancers16213564 · Cited by 17

Ecrg4 contributes to the anti-glioma immunosurveillance through type-I interferon signaling

Moriguchi, T., Kaneumi, S., Takeda, S., Enomoto, K., Mishra, S. K., Miki, T., Koshimizu, U., Kitamura, H., & Kondo, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1242547 · Cited by 16

Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells

Tarasova, I. A., Tereshkova, A. V., Lobas, A. A., Solovyeva, E. M., Sidorenko, A. S., Gorshkov, V., Kjeldsen, F., Bubis, J. A., Ivanov, M. V., Ilina, I. Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22751 · Cited by 16

TREX1 is a checkpoint for innate immune sensing of DNA damage that fosters cancer immune resistance

Demaria, S., & Vanpouille‐Box, C. (2017) · Emerging Topics in Life Sciences · doi:10.1042/etls20170063 · Cited by 17

Breast Cancer Vaccine Containing a Novel Toll-like Receptor 7 Agonist and an Aluminum Adjuvant Exerts Antitumor Effects

Zhang, S., Liu, Y., Zhou, J. Y., Wang, J., Jin, G., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315130 · Cited by 16

Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment

Nie, Z., Aboulnasr, F., Natesampillai, S., Burke, S. P., Krogman, A., Bren, G. D., Chung, T. D. Y., Anderson, J. R., Smart, M. K., Katzmann, D. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1701113 · Cited by 16

β‐catenin regulates IRF3‐mediated innate immune signalling in colorectal cancer

Ding, C., He, J., Zhao, J., Li, J., Chen, J., Liao, W., Zeng, Y. A., Zhong, J., Wei, C., Zhang, L., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12464 · Cited by 16

Malignant cell-specific pro-tumorigenic role of type I interferon receptor in breast cancers

Odnokoz, O., Yu, P., Peck, A. R., Sun, Y., Kovatich, A. J., Hooke, J. A., Hu, H., Mitchell, E. P., Rui, H., & Fuchs, S. Y. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1750297 · Cited by 16

2′–5′ Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons

Sim, C. K., Cho, Y. S., Kim, B., Baek, I., Kim, Y.-J., & Lee, M. S. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1830-9 · Cited by 16

Ketogenesis instigates immune suppression in enzalutamide resistant prostate cancer via OTUD7B β-hydroxybutyrylation

Jiang, H., Zeng, Y., Ning, W., Hong, J., Zhu, M., Li, P., Ye, F., Chen, Z., Chen, H., Chen, W., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217808 · Cited by 15

Tumor microenvironment-responsive DNA-based nanomedicine triggers innate sensing for enhanced immunotherapy

Li, J., Han, X., Gao, S., Yan, Y., Li, X., & Wang, H. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-02132-6 · Cited by 15

Prognosis prediction and risk stratification of breast cancer patients based on a mitochondria-related gene signature

Wang, Y., Wang, D., Bu, K., Gao, J., & Zhang, B. (2024) · Scientific Reports · doi:10.1038/s41598-024-52981-w · Cited by 15

Targeting metabolic sensing switch GPR84 on macrophages for cancer immunotherapy

Li, J., Ma, A., Zhang, R., Yao, C., Bolyard, C. M., Zhao, B. L., Wang, C., Pich, T., Li, W., Sun, N., et al. (2024) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03603-3 · Cited by 15

SIRT1 ISGylation accelerates tumor progression by unleashing SIRT1 from the inactive state to promote its deacetylase activity

Kang, J. A., Kim, Y. J., Jang, K. Y., Moon, H. W., Lee, H., Lee, S., Song, H. K., Cho, S. W., Yoo, Y. S., Han, H. G., et al. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01194-2 · Cited by 15

c-MPL provides tumor-targeted T-cell receptor-transgenic T cells with costimulation and cytokine signals

Nishimura, C., Brenner, D. A., Mukherjee, M., Hirsch, R. A., Ott, L. C., Wu, M., Liu, H., Dakhova, O., Orange, J. S., Brenner, M. K., et al. (2017) · Blood · doi:10.1182/blood-2017-02-769463 · Cited by 15

Type I Interferon Signaling Is Required for CpG-Oligodesoxynucleotide-Induced Control of Leishmania major, but Not for Spontaneous Cure of Subcutaneous Primary or Secondary L. major Infection

Schleicher, U., Liese, J., Justies, N., Mischke, T., Haeberlein, S., Sebald, H., Kalinke, U., Weiß, S., & Bogdan, C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00079 · Cited by 15

MEK1/2 Inhibitors Unlock the Constrained Interferon Response in Macrophages Through IRF1 Signaling

Yang, L., & Ding, J. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02020 · Cited by 15

Type I Interferons as Joint Regulators of Tumor Growth and Obesity

Gessani, S., & Belardelli, F. (2021) · Cancers · doi:10.3390/cancers13020196 · Cited by 15

Inflammation-Immunity-Nutrition Score: A Novel Prognostic Score for Patients with Resectable Colorectal Cancer

Li, X., Yao, S., He, Y., Ke, S., Ma, Y., Lü, P., Nie, S., Wei, S., Liang, X., & Liu, L. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s322260 · Cited by 15

High Expression of Interferon Pathway Genes CXCL10 and STAT2 Is Associated with Activated T-Cell Signature and Better Outcome of Oral Cancer Patients

Huang, Y.-C., Huang, J.-L., Tseng, L.-C., Yu, P.-H., Chen, S., & Lin, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12020140 · Cited by 15

The redox cycling of STAT2 maintains innate immune homeostasis

Xue, B., Li, H., Liu, S., Feng, Q., Xu, Y., Deng, R., Chen, S., Wang, J., Li, X., Wan, M., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111215 · Cited by 16

Exploring the immunomodulatory role of virtual memory CD8+ T cells: Role of IFN gamma in tumor growth control

Savid-Frontera, C., Viano, M. E., Baez, N. S., Lidon, N. L., Fontaine, Q., Young, H. A., Vimeux, L., Donnadieu, E., & Rodriguez‐Galán, M. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.971001 · Cited by 15

The molecular basis of immuno-radiotherapy

Koukourakis, I. M., TINIAKOS, D. G., Kouloulias, V., & Zygogianni, A. G. (2022) · International Journal of Radiation Biology · doi:10.1080/09553002.2023.2144960 · Cited by 17

Mechanism of SUMOylation-Mediated Regulation of Type I IFN Expression

Du, L., Liu, W., Rosen, S. T., & Chen, Y. (2023) · Journal of Molecular Biology · doi:10.1016/j.jmb.2023.167968 · Cited by 15

Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review

Lam, B. M., & Verrill, C. L. (2023) · Cancers · doi:10.3390/cancers15041164 · Cited by 15

Highlights into historical and current immune interventions for cancer

Cole, K., Al-Kadhimi, Z. S., & Talmadge, J. E. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109882 · Cited by 15

Neoadjuvant Radiochemotherapy Significantly Alters the Phenotype of Plasmacytoid Dendritic Cells and 6-Sulfo LacNAc+ Monocytes in Rectal Cancer

Wagner, F., Hölig, U., Wilczkowski, F., Plesca, I., Sommer, U. J., Wehner, R., Kießler, M., Jarosch, A., Flecke, K., Arsova, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00602 · Cited by 15

Underexpression of Specific Interferon Genes Is Associated with Poor Prognosis of Melanoma

Zainulabadeen, A., Yao, P., & Zare, H. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170025 · Cited by 15

Revisiting Lung Cancer Metastasis: Insight From the Functions of Long Non-coding RNAs

Huang, P., Zhu, S., Liang, X., Zhang, Q., Liu, C., & Song, L. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211038488 · Cited by 14

Oncolytic Viruses for the Treatment of Bladder Cancer: Advances, Challenges, and Prospects

Hu, H., Xia, Q., Hu, J., & Wang, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236997 · Cited by 14

Mining TCGA Database for Genes with Prognostic Value in Breast Cancer

Filippi, A., & Mocanu, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021622 · Cited by 14

Phospholipase A and acyltransferase 4/retinoic acid receptor responder 3 at the intersection of tumor suppression and pathogen restriction

Zhao, J., Yuan, X.-K., Luo, R.-Z., Wang, L., Gu, W., Yamane, D., & Feng, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1107239 · Cited by 14

Pattern recognition receptors and their nano-adjuvants for cancer immunotherapy

Li, Z., Rana, I., Park, G. T., Lee, J., Park, C. E., & Nam, J. (2023) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-023-00633-y · Cited by 14

The UBA1–STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade

Bao, Y., Cruz, G., Zhang, Y., Qiao, Y., Mannan, R., Hu, J., Yang, F., Gondal, M. N., Shahine, M., Kang, S., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0435 · Cited by 16

SILAC-Based Quantitative Proteomic Analysis of Oxaliplatin-Resistant Pancreatic Cancer Cells

Kim, Y. E., Kim, E.-K., Song, M.-J., Kim, T., Jang, H. H., & Kang, D. (2021) · Cancers · doi:10.3390/cancers13040724 · Cited by 14

Oncolytic virotherapy: Potentially a game-changing tumor treatment

Keßler, T., & Wick, W. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.05.014 · Cited by 14

Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis

Bufalieri, F., Basili, I., Marcotullio, L. D., & Infante, P. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.710171 · Cited by 14

Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC

Cattolico, C., Bailey, P., & Barry, S. T. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.816517 · Cited by 17

Manipulation of the tumor immuno-microenvironment via TAM-targeted expression of transcription factors

Musick, M., & Yu, X. (2022) · Immunologic Research · doi:10.1007/s12026-022-09277-w · Cited by 14

Immunogenic Cell Death Enhances Immunotherapy of Diffuse Intrinsic Pontine Glioma: From Preclinical to Clinical Studies

Liu, G., Qiu, Y., Zhang, P., Chen, Z., Chen, S., Huang, W., Wang, B., Yu, X., & Guo, D. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091762 · Cited by 14

Effect of platinum‑based chemotherapy on the expression of natural killer group�2 member�D ligands, programmed cell death‑1 ligand�1 and HLA class�I in non‑small cell lung cancer

Okita, R., Maeda, A., Shimizu, K., Nojima, Y., Saisho, S., & Nakata, M. (2019) · Oncology Reports · doi:10.3892/or.2019.7185 · Cited by 14

Molecular profiling of immune cell-enriched Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) interacting protein USP13

SÜT, B. B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118170 · Cited by 15

Genome instability and crosstalk with the immune response

Chabanon, R. M., Danlos, F. X., Ouali, K., & Postel-Vinay, S. C. (2025) · Genome Medicine · doi:10.1186/s13073-025-01509-6 · Cited by 16

Identification of Cytosolic DNA Sensor cGAS-STING as Immune-Related Risk Factor in Renal Carcinoma following Pan-Cancer Analysis

Wu, Z., Lin, Y., Liu, L.-M., Hou, Y., Qin, W., Zhang, L., Jiang, S., Yang, Q., & Bai, Y. (2022) · Journal of Immunology Research · doi:10.1155/2022/7978042 · Cited by 13

cGAS-dependent proinflammatory and immune homeostatic effects of the microtubule-targeting agent paclitaxel

Serpico, A. F., Pisauro, C., & Grieco, D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1127623 · Cited by 14

Innate immune response restarts adaptive immune response in tumors

Li, W.-S., Zhang, Q., Li, Q., Liu, S.-Y., Yuan, G.-Q., & Pan, Y.-W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1260705 · Cited by 14

Safe Induction of Acute Inflammation with Enhanced Antitumor Immunity by Hydrogel‐Mediated Outer Membrane Vesicle Delivery

Xu, W., Hao, X., Li, Y., Tang, Y., Qiu, X., Zhou, M., Liu, J., Huang, S. Q., Liao, D., Hu, X.-B., et al. (2024) · Small Methods · doi:10.1002/smtd.202301620 · Cited by 13

Dual and multi-immune activation strategies for emerging cancer immunotherapy

Zhang, Y., Liu, L., He, H., Sun, Y., & Zhong, Z. (2024) · Materials Today · doi:10.1016/j.mattod.2024.08.006 · Cited by 13

Nanoparticle approaches for manipulating cytokine delivery and neutralization

Wang, R., Kubiatowicz, L. J., Zhang, R., Bao, L., Fang, R. H., & Zhang, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1592795 · Cited by 13

Prophylactic Vaccines for Nonviral Cancers

Scott, B., Yarchoan, M. M., & Jaffee, E. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050558 · Cited by 13

Breaking self-tolerance during autoimmunity and cancer immunity: Myeloid cells and type I IFN response regulation

Tarbell, K. V., & Egen, J. G. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mir1017-400r · Cited by 15

Activation of the ILT7 receptor and plasmacytoid dendritic cell responses are governed by structurally-distinct BST2 determinants

Bego, M. G., Miguet, N., Laliberté, A., Aschman, N., Gérard, F. C. A., Merakos, A. A., Weissenhorn, W., & Cohen, É. A. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008481 · Cited by 14

Middle East Respiratory Syndrome Coronavirus-Encoded ORF8b Inhibits RIG-I-Like Receptors in a Differential Mechanism

Lee, J. Y., Kim, S., & Myoung, J. (2019) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1911.11024 · Cited by 13

Targeting Cancer Stem Cells through Epigenetic Modulation of Interferon Response

Huang, J.-L., Chen, S., & Lin, C. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12040556 · Cited by 13

Pan-cancer analysis identifies protein arginine methyltransferases PRMT1 and PRMT5 and their related signatures as markers associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma

Wang, J., Wu, M., Sun, J., Chen, M., Zhang, Z., Yu, J., & Chen, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22088 · Cited by 14

Recent advances in mRNA‐based vaccine for cancer therapy; bench to bedside

Kenoosh, H. A., Pallathadka, H., Hjazi, A. M., Al‐Dhalimy, A. M. B., Zearah, S. A., Ghildiyal, P., Al‐Mashhadani, Z. I., Mustafa, Y. F., Hizam, M. M., & Elawady, A. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3954 · Cited by 15

Converting Lymphoma Cells into Potent Antigen-Presenting Cells for Interferon-Induced Tumor Regression

Liao, J., Luan, Y., Ren, Z., Liu, X., Xue, D., Xu, H., Sun, Z., Yang, K., Peng, H., & Fu, Y. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0221 · Cited by 13

Suppression of CCDC6 sensitizes tumor to oncolytic virus M1

Liu, Y., Li, K., Zhu, W., Zhang, H., Huang, W., Liu, X., Lin, Y., Cai, J., Yan, G., Qiu, J., et al. (2020) · Neoplasia · doi:10.1016/j.neo.2020.12.003 · Cited by 13

Interferons: Cellular and Molecular Biology of Their Actions ☆

Kalvakolanu, D. V., Nallar, S. C., & Kalakonda, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.96116-6 · Cited by 13

Antitumor effect of an adeno-associated virus expressing apolipoprotein A-1 fused to interferon alpha in an interferon alpha-resistant murine tumor model

Vásquez, M., Cervantes, V. P., Aranda, F., Ardaiz, N., Gomar, C., & Berraondo, P. (2016) · Oncotarget · doi:10.18632/oncotarget.14127 · Cited by 13

HIV immunotherapy comes of age: implications for prevention, treatment and cure

Routy, J., Mehraj, V., & Cao, W. (2015) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1112269 · Cited by 13

Controlling the STING pathway to improve immunotherapy

Wilson, J. T. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01637-x · Cited by 14

Identification of a risk prediction model for clinical prognosis in HER2 positive breast cancer patients

Zhou, D., Wu, Y., Jiang, K., Xu, F., Hong, R., & Wang, S. (2021) · Genomics · doi:10.1016/j.ygeno.2021.10.010 · Cited by 12

Cellular Target Deconvolution of Small Molecules Using a Selection-Based Genetic Screening Platform

Zhao, J., Tang, Z., Selvaraju, M., Johnson, K. A., Douglas, J. T., Gao, P. F., Petrassi, H. M., Wang, M. Z., & Wang, J. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00609 · Cited by 12

SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy

Luo, X., Zhang, Z., Li, S., Wang, Y., Sun, M., Hu, D. X., Jiang, J., Wang, Y., Ji, X., Chen, X., et al. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.111376 · Cited by 12

Activation of RIG‐I/MDA5 Signaling and Inhibition of CD47‐SIRPα Checkpoint with a Dual siRNA‐Assembled Nanoadjuvant for Robust Cancer Immunotherapy

Xu, X., Li, S., Yu, W., Yao, S., Fan, H., & Guo, Z. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202318544 · Cited by 12

DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy

Cifrić, S., Turi, M., Folino, P., Clericuzio, C., Barello, F., Maciel, T., Anderson, K. C., & Gullà, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0558 · Cited by 12

Carbon Ion Irradiation Activates Anti-Cancer Immunity

Sudo, M., Tsutsui, H., & Fujimoto, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052830 · Cited by 12

Tuning cellular metabolism for cancer virotherapy

Xiong, D., Wang, Q., Wang, W., & Sun, Z. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216924 · Cited by 12

A modified HSV-1 oncolytic virus reconciles antiviral and antitumor immunity via promoting IFNβ expression and inhibiting PKR

Shen, Y., Zhao, X., Chen, L., Wang, X., Wang, D., Zhang, H., Zheng, Z., Huang, W., Zheng, C., Chen, Y., et al. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.133297 · Cited by 12

GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-β axis-mediated antitumor immunity

Jin, Z., Wang, H., Tang, R., Pan, B., Lee, H.-J., Liu, S., Wang, L., Qin, J., & Xu, M. (2024) · Oncogene · doi:10.1038/s41388-024-03107-z · Cited by 12

Bendamustine–rituximab elicits dual tumoricidal and immunomodulatory responses via cGAS–STING activation in diffuse large B-cell lymphoma

Xiao, R., Zhao, W., Lin, W., Xiao, Y., Ren, J., Zhou, Y., Meng, W., Bi, E., & Jiang, L. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009212 · Cited by 12

Glyco-Nanoadjuvants: Sugar Structures on Carriers of a Small Molecule TLR7 Ligand Affect Their Immunostimulatory Activities

Shinchi, H., Yuki, M., Yamauchi, T., Niimura, M., Wakao, M., Cottam, H. B., Hayashi, T., Carson, D. A., Moroishi, T., & Suda, Y. (2021) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c01639 · Cited by 12

Type I Interferon Signaling Accelerates Liver Regeneration by Metabolic Modulation in Noninfectious Conditions

Wu, M.-S., Kuo, Y.-P., Lo, Y.-C., Tsai, D.-J., Lai, C.-Y., Chuang, T., Lin, S., Tsai, W.-T., Chung, P., & Yu, G. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.03.006 · Cited by 12

SADS‐CoV nsp1 inhibits the IFN‐β production by preventing TBK1 phosphorylation and inducing CBP degradation

Xiang, Y., Mou, C., Shi, K., Chen, X., Meng, X., Bao, W., & Chen, Z. (2023) · Journal of Medical Virology · doi:10.1002/jmv.29104 · Cited by 12

TTK inhibition activates STING signal and promotes anti-PD1 immunotherapy in breast cancer

Hu, X., Li, G., Li, S., Wang, Q., Wang, Y., Zhang, P., Yang, T., Yang, B., Yu, L., & Liu, Z. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.149388 · Cited by 12

Gene Expression Signatures of a Preclinical Mouse Model during Colorectal Cancer Progression under Low-Dose Metronomic Chemotherapy

Ho-Xuan, H., Lehmann, G. J., Glažar, P., Gypas, F., Eichner, N., Heizler, K., Schlitt, H. J., Zavolan, M., Rajewsky, N., Meister, G., et al. (2020) · Cancers · doi:10.3390/cancers13010049 · Cited by 13

Combining inhibition of immune checkpoints and PARP: rationale and perspectives in cancer treatment

Catalano, M., Iannone, L. F., Cosso, F., Generali, D., Mini, E., & Roviello, G. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2158813 · Cited by 13

STAT3 inhibition for cancer therapy: Cell-autonomous effects only?

Kroemer, G., Galluzzi, L., & Zitvogel, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1126063 · Cited by 12

Radiotherapy for HPV-related cancers: prediction of therapeutic effects based on the mechanism of tumor immunity and the application of immunoradiotherapy

Someya, M., Fukushima, Y., Hasegawa, T., Tsuchiya, T., Kitagawa, M., Gocho, T., Mafune, S., Ikeuchi, Y., Kozuka, Y., Hirohashi, Y., et al. (2022) · Japanese Journal of Radiology · doi:10.1007/s11604-021-01231-4 · Cited by 11

The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications

Zhou, Y., Liu, X., Gao, W., Luo, X., Lv, J., Wang, Y., & Liu, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23919 · Cited by 11

GRP78 Nanobody‐Directed Immunotoxin Activates Innate Immunity Through STING Pathway to Synergize Tumor Immunotherapy

Wang, H., Zhou, R., Xu, C., Dai, L., Hou, R., Zheng, L., Fu, C., Shi, G., Wang, J., Yang, L., et al. (2025) · Advanced Science · doi:10.1002/advs.202408086 · Cited by 11

Siglec-15 antibody–GM-CSF chimera suppresses tumor progression via reprogramming tumor-associated macrophages

Ma, Z., Hao, X., Qu, S., Zhang, Q., Luo, J., Li, H., Liu, J., Dai, W., Li, J., Gu, S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010580 · Cited by 11

Defects in the necroptosis machinery are a cancer resistance mechanism to checkpoint inhibitor immunotherapy

Sax, A., May, P., Enßle, S., Soliman, N., Nedelko, T., Mandracci, G., Stögbauer, F., Joachim, L., Winter, C., Bassermann, F. C., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010433 · Cited by 11

Impact of Interferon-alpha1b (IFN-α1b) on Antitumor Immune Response: An Interpretation of the Promising Therapeutic Effect of IFN-alpha1b on Melanoma

Liu, Y., Ma, J., Yang, Y., Liu, L., Zhu, G., Wang, X., Wang, S., Guo, W., Yue, Q., Zhao, T., et al. (2020) · Medical Science Monitor · doi:10.12659/msm.922790 · Cited by 11

Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy

Huang, X., Tang, T., Zhang, G., Hong, Z., Xu, J., Yadav, D. K., Bai, X., & Liang, T. (2020) · npj Precision Oncology · doi:10.1038/s41698-020-00136-1 · Cited by 11

Type I interferons and dendritic cells in cancer immunotherapy

(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124

The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation

Musella, M., Galassi, C., Manduca, N., & Sistigu, A. (2021) · Biology · doi:10.3390/biology10090856 · Cited by 45

Type I Interferons and Natural Killer Cell Regulation in Cancer

Müller, L., Aigner, P., & Stoiber, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00304 · Cited by 173

The added value of type I interferons to cytotoxic treatments of cancer

Bracci, L., Sistigu, A., Proietti, E., & Moschella, F. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.06.008 · Cited by 20

Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications

Musella, M., Manic, G., Maria, R. D., Vitale, I., & Sistigu, A. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1314424 · Cited by 147